Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT
Silvio Danese1, Axel Dignass2, Katsuyoshi Matsuoka3
1Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milano, Italy.
Journal of Crohn'S & Colitis
|June 13, 2024
Summary
Mirikizumab effectively controlled ulcerative colitis symptoms, including stool frequency and rectal bleeding, within weeks and sustained this improvement over 52 weeks. This anti-IL-23p19 antibody demonstrated significant efficacy in achieving comprehensive symptom control for UC patients.
Area of Science:
- Gastroenterology
- Immunology
- Clinical Trials
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease with debilitating symptoms.
- Mirikizumab, an anti-interleukin-23p19 antibody, has shown promise in treating UC.
- Previous trials (LUCENT-1/-2) established mirikizumab's efficacy and safety.
Purpose of the Study:
- To evaluate mirikizumab's efficacy in achieving symptom control in UC patients.
- To assess the time to symptom improvement during induction and maintenance phases.
- To determine the achievement of comprehensive symptom control and identify prognostic indicators for early remission.
Main Methods:
- Analysis of data from the LUCENT Phase 3 trials (LUCENT-1 and LUCENT-2).
- Comparison of symptomatic endpoints over 52 weeks against placebo.
- Subgroup analyses for patients with prior biologic or tofacitinib failure and regression analyses for prognostic indicators.
Main Results:
- Mirikizumab rapidly reduced stool frequency, rectal bleeding, bowel urgency, and fatigue by Week 2.
- Significant improvement in abdominal pain was observed by Week 4.
- Higher rates of symptomatic remission and comprehensive symptom control were achieved with mirikizumab compared to placebo at Weeks 12 and 52, sustained throughout the maintenance period.
Conclusions:
- Mirikizumab demonstrated significant efficacy in achieving and sustaining symptom control in patients with moderately to severely active UC.
- The anti-IL-23p19 antibody provided comprehensive symptom control over 52 weeks.
- Treatment effects were consistent across patient subgroups, including those with prior treatment failures.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:21Drugs for Treatment of Constipation-Predominant IBS
155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
01:17Drugs for Treatment of Diarrhea-Predominant IBS
157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130